PRODUCT

PE-22-28 (Mini-Spadin)

No short description available.

Molecular Info

Chain Length:7 amino acids
Sequence Type:Linear heptapeptide
Molecular Weight:773.89 Da
Amino Acid Sequence:Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR)
Modification:Shortened analog of Spadin (PE 12-28, 17 amino acids). Represents the C-terminal fragment responsible for TREK-1 binding activity. Analog G/A-PE 22-28 (glycine-to-alanine substitution) shows similar or improved activity

Research Indications

Mood

effective

Depression Research
Primary focus - rapid antidepressant effects in 4 days vs weeks for SSRIs

Cognitive

effective

Neurogenesis / Cognitive
Hippocampal neurogenesis and synaptogenesis; CREB activation for memory

Anxiety

effective

Anxiety Research
Anxiolytic effects observed in preclinical models alongside antidepressant activity

Neuroprotection

effective

Neuroprotection / Stroke
TREK-1 blockade may reduce ischemic damage and support neuronal survival

Interactions

SSRIs (Fluoxetine, Sertraline)

Monitor Combination

Both target serotonergic pathways via different mechanisms. Fluoxetine also weakly inhibits TREK-1. Theoretical additive effects - monitor for excessive serotonergic activity

Semax / NA-Semax

Potentially Synergistic

Both support neurogenesis and cognitive function via different mechanisms. Semax acts through BDNF/NGF; PE-22-28 via TREK-1 inhibition. Complementary nootropic stack

Selank

Synergistic

Both have anxiolytic and neuroprotective properties. Selank modulates GABA; PE-22-28 blocks TREK-1 potassium channels. Different mechanisms for anxiety/mood support

Dihexa

Potentially Synergistic

Both promote neurogenesis and synaptic plasticity through different pathways. Dihexa acts via HGF/c-Met; PE-22-28 via TREK-1/5-HT enhancement. Complementary neuroplasticity targets

Cerebrolysin

Compatible

Both support neuroplasticity and neuroprotection. Cerebrolysin provides neurotrophic factors; PE-22-28 enhances 5-HT transmission and neurogenesis via TREK-1 blockade

BPC-157

Compatible

BPC-157 has shown neuroprotective effects and dopamine system modulation. Different mechanisms from PE-22-28's TREK-1 action. No contraindications identified

Potassium Channel Modulators

Use Caution

Other drugs affecting potassium channels could have additive or antagonistic effects. PE-22-28 is selective for TREK-1 but caution warranted with K+ channel drugs

MAOIs

Avoid Combination

PE-22-28 increases serotonergic neurotransmission. Combining with MAOIs could theoretically increase serotonin syndrome risk. No clinical data - avoid combination

Dosage Protocols

Preclinical Antidepressant Studies (Mouse):3-4 mcg/kgOnce daily
Preclinical Oral Studies (Mouse):1 mg/kgOnce daily
Research Protocol (Human Equivalent - Theoretical):50-100 mcgOnce daily
Research Protocol (Conservative):100-200 mcgOnce daily

Route:injectable

Reconstitution

Remove PE-22-28 vial from refrigerator and allow to reach room temperature
Clean the rubber stopper with alcohol swab
Determine reconstitution volume (e.g., 2 mL BAC water for 10 mg vial = 5 mg/mL or 5000 mcg/mL)
Draw bacteriostatic water into syringe slowly
Inject BAC water slowly down the inside wall of the vial - do not spray directly on powder
Gently swirl vial until powder is completely dissolved - do not shake
Solution should be clear and colorless
Label vial with reconstitution date and concentration
Store reconstituted solution in refrigerator at 2-8°C
Use within 4-6 weeks of reconstitution

Route:injectable

PE-22-28 (Mini-Spadin)

Resources

Categories

Company